AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Centrosomal protein of 57 kDa

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q86XR8

UPID:

CEP57_HUMAN

Alternative names:

FGF2-interacting protein; Testis-specific protein 57; Translokin

Alternative UPACC:

Q86XR8; A0PJH1; A8K5D0; B4DDP5; F5H5F7; Q14704; Q5JB46; Q8IXP0; Q9BVF9

Background:

Centrosomal protein of 57 kDa, also known as FGF2-interacting protein, Testis-specific protein 57, and Translokin, plays a pivotal role in cell division and growth. It is essential for microtubule attachment to centrosomes and may facilitate the formation of ring-like structures around microtubules. Additionally, it mediates the nuclear translocation and mitogenic activity of the internalized growth factor FGF2.

Therapeutic significance:

The protein's involvement in Mosaic variegated aneuploidy syndrome 2, characterized by severe developmental disorders and a high risk of malignancy, underscores its potential as a target for therapeutic intervention. Understanding the role of Centrosomal protein of 57 kDa could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.